admin – page 4 – eisai china lnc.-威尼斯人888

entries by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (aed) fycompa® (product name in china: 卫克泰®, generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in china by the national medical products administration.

2020/10/16 by

the university of tokyo (president: makoto gonokami, “the university of tokyo”) and eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “protein degradation drug discovery”. the research time span will last five years from october 1, 2020 to september 30, 2025.

2020/10/8 by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a joint research agreement with four research organizations (kan research institute, national center for global health and medicine, nagasaki university, and yokohama city university) in japan concerning the “development of therapeutics to prevent the aggravation of the novel coronavirus infectious disease (covid-19)” (grant number: 20fk0108255), which is a research project with eisai as the representative research organization.

2020/10/6 by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and seikagaku corporation (headquarters: tokyo, president: ken mizutani, “seikagaku”) announced today that the companies have entered into an agreement for the marketing alliance in south korea for si-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by seikagaku. eisai and seikagaku signed an agreement for the co-development and marketing alliance in china of si-613 on april 1, 2020. thus, south korea becomes the second country for the companies to conclude the marketing alliance for si-613.

2020/9/30 by

gilead sciences, inc. (nasdaq: gild) and eisai co., ltd. (tokyo, japan) today announced that the japanese ministry of health, labour and welfare (mhlw) has granted gilead k.k. (tokyo, japan) regulatory approval of jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, jak1 preferential inhibitor for the treatment of rheumatoid arthritis (ra) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

2020/9/25 by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that it has received a positive opinion from the european medicines agency (ema)’s committee for medicinal products for human use (chmp) on the license extension application submitted by its u.k. subsidiary eisai ltd. regarding the use of its in-house discovered and developed anti-epileptic agent (aed) fycompa® (generic name: perampanel) in the treatment of pediatric patients.

2020/9/23 by

new results include findings from the phase 2 leap-004 trial showing an orr of 21.4% in patients with unresectable or advanced melanoma who had previously progressed on an anti-pd-1/pd-l1 therapy

2020/9/23 by

eisai china inc. successfully held “2020 ads summit”

on september 20, 2020, the “2020 ads summit” (ads: advance dementia science) hosted by eisai china inc. was successfully held. featuring the theme of “run into the next decade”, the summit was made up of one main venue (online) and four sub-venues (offline) in beijing, shanghai, guangzhou and chengdu. famous experts from china, japan and south korea and nearly 1,000 guests online and offline made exchanges on the frontier progress of dementia and cognitive disorders.

2020/9/20 by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that the latest results from the cohort targeting patients with her2-negative breast cancer in the phase i clinical trial for the new liposomal formulation (e7389-lf) of the in-house discovered anti-cancer treatment halaven® (generic name: eribulin mesylate, “eribulin”) were presented (abstract number: 346p) at the european society for medical oncology (esmo) virtual congress 2020.

2020/9/18 by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a series of abstracts will be presented at the european society for medical oncology (esmo) virtual congress 2020 from september 19 to 21, 2020. the abstracts highlight updates regarding eisai’s in-house discovered lenvima® (lenvatinib mesylate, the orally available kinase inhibitor, “lenvatinib”), halaven® (eribulin mesylate, halichondrin class microtubule dynamics inhibitor, “eribulin”) and its liposomal formulation.

2020/9/11 by

1066vip威尼斯 copyright(c) 2011 eisai china lnc.all rights reserved.

沪公网安备31010602001439号

customer service hotline

021-62881220

links


• 已上市替普瑞酮胶囊铬限量检验报告公示说明

more information

• privacy policy
• legal notices
• accessibility

网站地图